(+) Epicatechin to Treat Friedreich's Ataxia

Inclusion Criteria:

- Confirmed diagnosis of Friedreich's Ataxia (FA) by Frataxin genetic testing and/or
Frataxin enzyme analysis

- Between age 10 and 50 years of age, inclusive

- Body weight of 25 kilograms or higher

- Minimum of one affected organ (cardiac or neurological) system, as evidenced by
clinical signs/symptoms

- Disease duration ≤7 years, based on onset date of FA symptoms

- Has no known contraindication to gadolinium contrast such as severe allergy or
Glomerular Filtration Rate <30 ml/min/m^2.

- Has no known contraindication to non-contrast Magnetic Resonance Imaging (MRI)
evaluation such as pacemaker or magnetically active metal fragments.

- Women of childbearing age must:

- Have a negative pregnancy human chorionic gonadotropin test prior to receiving
study drug.

- Agree to use contraception for the duration of the study drug dosing, plus 1
month after completion of the study.

Exclusion Criteria:

- Advanced cardiac failure, New York Heart Association (NYHA) Classification Scale-Class
IV (advanced stage heart failure)

- Clinically significant comorbidities that may also lead to cardiomyopathy, for example
long standing hypertension, familial cardiomyopathy.

- Clinically significant comorbidities that would, in the opinion of the investigators,
compromise the interpretation of test results.

- Pregnant, breast-feeding or planning to become pregnant during study timeframe.

- Patients with contraindications to regadenoson, i. e. second- or third-degree
atrioventricular (AV) block or sinus node dysfunction. Has received an investigational
drug within thirty (30) days of baseline visit.

- Thrombocytopenia (<125 x 10^9/Liter) or prolonged Prothrombin Time/Partial
Thromboplastin Time (PT/PTT) at baseline.

- Clinically significant hypotension (systolic blood pressure <90) due to heart failure
or other conditions.